CAR-T in ALL: Records Reveal Direct Costs for Hospitalization Approach $300K
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981.
Acute Lymphoblastic Leukemia
CAR-NK Cells Make Their Debut in Hematologic Cancers
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
Expert Opinion on Addressing Psychosocial Needs of Children Receiving CAR-T Therapy
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Is Tisagenlecleucel for Relapsed Pediatric Acute Lymphoblastic Leukemia Cost-Effective?
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Novel Heavy Metal Scoring System May Predict Survival Outcomes in Acute Myeloid Leukemia
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.
Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
No Benefit With Intensified Postinduction in Pediatric Standard-Risk Acute Lymphoblastic Leukemia
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Risk Score Developed to Help ID Heart Failure Risk in Leukemia
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Stem Cell Transplant May Improve Survival in Patients With Relapsed/Refractory ALL
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
Next post in Hematologic Cancers
